Table 2.

Completed CD19 CAR-T clinical trials for B-cell non-Hodgkin lymphoma

NCT Number	Phase	Status	Locations	Clinical outcomes
NCT01593696	Phase I	Completed	National Institutes of Health Clinical Center, 9000 RockvillePike, Bethesda, Maryland, United States	The CR rate was 59.6% (31/52). The occurrence rate of serious adverse events and high grade CRS were 26.9% (14/52) and 9.6% (5/52).
NCT02132624	Phase I / IIa	Completed	Uppsala University Hospital, Dept of Oncology, Uppsala,Sweden	Six of the 15 patients had complete responses (4/11 lymphoma and 2/4 ALL). Three patients developed severe CRS in 15 patients and 2 patients developed high grade ICANS.
NCT02030834	Phase IIa	Completed	Abramson Cancer Center of the University of Pennsylvania,Philadelphia, Pennsylvania, United States	The objective response rate was 64% (18/28). Occurrence rate of serious CRS and ICANS were 18% (5/28) and 11% (3/28)
NCT01626495	Phase I /IIa	Completed	CHOP-http://www.chop.edu/service/oncology/pediatric-cancer-research/cart-19-trial.html, Philadelphia, Pennsylvania, UnitedStates	The CR rate was 25.8% (16/62) and CRi (complete remission with incomplete blood count recovery) rate was 61.3% (38/62).

Abbreviations: CR complete response, CRS cytokine release syndrome, ICANS immune effector cell-associated neurotoxicity syndrome, CRi complete remission with incomplete blood count recovery, ALL acute lymphoblastic leukemia